← Back to Treatments
🏅 FDA Orphan Designation

Oncoscint CR/OV

Satumomab pendetide

Manufacturer: Cytogen Corporation

Indicated for:
Small cell carcinoma of the ovaryOrphanMalignant tumor of fallopian tubesRare ovarian cancer

FDA-Approved Indications (3)

For determining the extent and location of extraphepatic malignant disease in patients with known colorectal and ovarian cancer.

For determining the extent and location of extraphepatic malignant disease in patients with known colorectal cancer

Population: patients with known colorectal cancer

For determining the extent and location of extraphepatic malignant disease in patients with known ovarian cancer

Population: patients with known ovarian cancer

Indications & Usage

For determining the extent and location of extraphepatic malignant disease in patients with known colorectal and ovarian cancer.

💙 Support Programs

View all →
Oncoscint CR/OV
Cytogen Corporation
Oncoscint CR/OV
Cytogen Corporation

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.